Method of treatment of mastitis in lactating sheep

FIELD: veterinary medicine.

SUBSTANCE: method comprises intramuscular administration of the tylosin-containing preparation at a dose of 0.05 ml/kg body weight once a day for 3-4 days in all forms of mastitis. The tylosin-containing preparation is used as the preparation of the following composition, wt %: colistin sulphate - 4.0-6.0; tylosin base - 4.0-6.0; benzyl alcohol - 4.0; water for injection - 15.0; 1,2-propylene glycol - 100.0%.

EFFECT: use of the claimed invention enables to improve the therapeutic efficacy of treatment of mastitis.

3 tbl, 3 ex

 

The invention relates to veterinary medicine, in particular to veterinary obstetrics, and can be used for the treatment of mastitis in sheep.

Inflammation of the breast - mastitis in sheep is widespread. During the year, mastitis perebivay from two to ten percent of ewes [Guseinov, E. M., Shabanov S. B., K. B. Hasanov Diagnosis and prevention of latent mastitis. Sheep 1993, No. 2. S. 37-38].

Mastitis in sheep occurs in most cases as a result of hit in the mammary gland of pathogenic microorganisms, mainly staphylococci, streptococci, Pasteurella. Infection occurs when lying down on an infected animal litter or suckling lambs sick and then healthy ewes, also through injury of the udder and teats caused by lambs (Goncharov, V. P. Prevention and treatment of mastitis in animals / V. P. Goncharov, V. A. Karpov, I. L. Yakimchuk // M - 1987. - 207 p.).

Mastitis occur predominantly acute and manifest themselves in the form of serous, catarrhal, purulent and hemorrhagic inflammation, and subclinical. The economic damage from this disease is decrease in milk production of ewes, treatment costs, premature culling, and treatment costs of the lambs [Nikitin V. J. Mastitis in sheep in the Stavropol region. Proceedings of Stavropol agricultural Institute, vol. 20,1965].

For the treatment of patients with mastitis of ewes used mainly various antimicrobial preparations containing antibiotics and sulfonamides.

Known analogue - method of treatment of mastitis in sheep, providing for intramuscular penicillin at a dose of 100000-200000 IU three times daily and oral administration norsulfazola 1-3 g per head 2 times a day. Simultaneously with intramuscular antibiotic, once a day to the affected share of the udder through the teat is introduced 50000-100000 UNITS of penicillin or streptomycin dissolved in 10 ml of saline. For-thinning fluid udder before application of drugs through the nipple administered warm 1-2% solution of bicarbonate of soda and are forced out. The course of treatment is 3-4 days [http://webmvc.com/bolezn/livestock/infect/cattle/mastitis.php].

The disadvantage of this method of treatment is repeated and the complexity of drug administration.

A method of treating mastitis in animals with the use of bicillin-3. The antibiotic was dissolved in sterile physiological solution and ewes administered intramuscularly in a dose of 10-20 thousand UNITS per 1 kg weight of the animal [Arkhangelsk I. Infectious mastitis of sheep. In the book: Diseases of sheep and goats. M., 1973].

The disadvantage of this method of treatment is the low efficiency of treatment.

Known analogue - agent for the treatment of mastitis in animals on the basis of tylosin [RU 2464988 C2, 27.1.2012]. Treatment is as follows: after milking on the teat skin and the mammillary region of the hole is applied and rubbed with a tool, comprising the following components: tylosin (0,5-1,0%), glycerin (5,0-10,0%), carbopol (0,15-0,2%), triethanolamine (0,02-0,03%), fir essential oil (0.1 to 0.3%) is water.

The disadvantage of this method of treatment is the low efficiency and the intensity of treatment (requires a lot of time to fixation of the animal, applying and rubbing the ointment into the skin of the breast).

The closest analogue is a method of treatment of large and small cattle for diseases of bacterial and mycoplasmal etiology, including mastitis, with the use of tylosin at a dose of 200 0,05-0,06 ml/kg animal body weight, intramuscularly, once a day for 3-5 days [instructions for use of tylosin 200 in bacterial infections in animals, number of registration certificate: 44-3-12.12-0836 No. PTS-3-2.9/00065].

The disadvantage of the prototype is a reduction of therapeutic efficacy used in the method of the drug associated with the development of resistance of microorganisms to its activetestsuite component - tylosin.

The technical result of the invention - increase therapeutic efficacy of treatment of mastitis in lactating sheep.

The technical result is achieved in that in the method of treating mastitis in Lac�arousih sheep, including intramuscular teleinterviewer of the drug in a dose of 0.05 ml/kg of body weight once a day for 3-4 days in all forms of mastitis, according to the invention as teleinterviewer using the drug following composition, wt.%:

Colistin sulfate4,0-6,0
Tylosin base4,0-6,0
The benzyl alcohol4,0
Water for injections15,0
1,2-propylene Glycol100.0%

The drug combination in the form of two antimicrobial components with different mechanism of action provides the best bactericidal and a therapeutic effect due to the expansion of the spectrum of antimicrobial activity, completion of gaps in the action of each component of the combination and prevent the formation of resistance of microorganisms.

The mechanism of antimicrobial action of macrolide antibiotics - tylosin - is inhibition of protein synthesis in microbial cells as a result of its interaction with aminoacyl-t-RNA and peptidyl-t-RNA to the ribosome of bacteria, this also blocks the formation of polysomal�'s functional complexes and broadcast-related t-RNA amino acids. For macrolides characteristic postantibiotic effect, which is manifested in the lack of effect of renewal of growth of bacteria, despite the removal of the antibiotic from the body, as well as anti-inflammatory and immunomodulatory effects [Klyuchnikov C. O., Boldyrev V. B., the use of the macrolides in children in modern conditions / / journal of pediatric pharmacology and nutrition / Volume 4. 2007, No. 3. - S. 16-23]. These antibiotics increase the activity of T-killer cells, accumulate in neutrophils and macrophages, increase their phagocytic activity and migration to the inflammatory focus [Dorozhkin, V. I.; Biryukova N. P., Antipov V. A. Testing of antimicrobial agents on the basis of tylosin in proc. scientific. Tr. Vivific "the Use of new diagnostic methods and pharmacological agents in the treatment and prevention of noncontagious illnesses of animals". Voronezh, 1993. - S. 26-30].

Colistin sulfate (polymyxin E) is polymyxin, produced by Bacillus polymyxa. Antibiotic active against Salmonella, E. coli, Pseudomonas, Shigella, Hemophilus, agrobacteria, Pasteurella, Bordetella, Klebsiella [Keskinen E. S., Semin G. J. evaluation of the clinical efficacy of Zitrocin" in the treatment of various infectious and inflammatory diseases in children / journal of pediatric pharmacology and nutrition / Volume 4. 2007, No. 5. Pp. 35-39. Shabunin S. V. Antimicrobial activity �farmacologisch songs / S. V. Shabunin // Veterinary Medicine. - 1999. - No. 9. - P. 47-48]. The mechanism of action of colistin is based on the destruction of the structure of the phospholipids of the cell membrane of the microbial cell. Damage to the membrane structure leads to a change in its permeability for both intra-and extracellular components [Devid Bernala, J. M. Llop, E. Fort, M. B. Badia, R. Jadar. Use colistin in the Treatment of Multie-Drug-Resistant Gram-Negative Infections / Am J health-Syst Pharm, 2005; 62 (1): 39-47].

The efficiency of the method of treating mastitis in sheep was conducted on lactating ewes Dagestan rocks, 2-4 Ocotal, weighing 35-40 kg, subclinical, serous, catarrhal and purulent-catarrhal forms of mastitis. According to the principle analogues animals were divided into two groups with regard to General condition, severity of the disease and under the same conditions of feeding and maintenance.

The diagnosis of the disease mastitis was determined comprehensively based on the clinical examination of animals, the results of bacteriological research, taking into account the epizootic situation in the economy.

For the animals throughout the whole experiment was performed daily clinical observations. The results of treatment were evaluated on the 3-4th day after the last administration of the drug, taking into account clinical examination of sheep and laboratory studies secret of the treated udder lobes. The studies were performed in three series of�itov.

Example 1. The research was conducted on 107 patients with mastitis ewes belonging to PC "Repairmen" of Gergebil district, the Republic of Dagestan.

Animals of the experimental group (n=58) was injected intramuscularly the drug according to the claimed invention in a dose of 0.05 ml/kg of animal weight once a day until clinical recovery, control (n=49), is the prototype drug in accordance with the instruction manual.

Test therapeutic efficacy was conducted on the background of the subcutaneous injection of oxytocin at a dose of 10 IU twice with an interval of 12 h and nademanee novocaine blockade by D. D. Logvinov by a double injection of 0.25% solution of novocaine at a dose of 0.5 ml per 1 kg of body weight at intervals of 48 h. the test Results are presented in table 1.

Subclinical mastitis
Table 1
The effectiveness of the proposed method for mastitis in lactating sheep in PC "Repairmen" of Gergebil district, the Republic of Dagestan.
MethodsThe treated goal.Recovery time, daysRecovered
ewes%
The inventive method182,5±0,31794,4
Method-prototype172,6±0,21588,2
Serous mastitis
The inventive method153,1±0,21493,3
Method-prototype123,6±0,3975,0
Catarrhal mastitis
The inventive method133,5±0,51184,6
Method-prototype114,0±0,3872,7
Purulent-catarrhal mastitis
The inventive method11 4,3±0,4981,8
Method-prototype104,9±0,4770,0

As follows from the presented data, therapeutic effectiveness of the treatment according to the method prototype was: with subclinical mastitis - 88,2%, sero - 75,0%, catarrhal - 72,7%, purulent-catarrhal - 70,0%.

The most high therapeutic efficiency is achieved when using the claimed method. With subclinical mastitis she was 94.4%, sero - 93,3%, with catarrhal - 84.6 per cent, of catarrhal-purulent - 81,8%, which is higher than when using the prototype method, respectively 6.2%, to 18.3%, 11.9% and 11.8 per cent.

Example 2. The studies were performed on 98 ewes OTF No. 4 PZ "Chokh" gunibsky district of the Republic of Dagestan.

Animals of the experimental group (n=56) was injected intramuscularly the drug for the claimed method in a dose of 0.05 ml/kg of animal weight once a day until clinical recovery, control (n=42) is a drug by the method prototype in accordance with the instruction manual.

Test therapeutic efficacy was conducted on the background of the subcutaneous injection of oxytocin at a dose of 10 IU twice with an interval of 12 h and nademanee novocaine blockade by D. D. Logvinov by a double �of reference of 0.25% solution of novocaine at a dose of 0.5 ml per 1 kg of body weight at intervals of 48 hours. The test results are presented in table 2.

Table 2
The effectiveness of the proposed method for mastitis in lactating sheep OTF No. 4 PZ "Chokh" gunibsky district of the Republic of Dagestan
MethodsThe treated goal.Recovery time, daysRecovered
ewes%
Subclinical mastitis
The inventive method172,2±0,71694,1
Method-prototype142,8±0,21285,7
Serous mastitis
The inventive method153,5±0,71493,3
Method-prototype123,6±0,41083,3
Catarrhal mastitis
The inventive method143,3±0,71392,8
Method-prototype83,6±0,4675,0
Purulent-catarrhal mastitis
The inventive method104,7±0,3990,0
Method-prototype84,7±0,3562,5

The most high therapeutic efficiency is achieved when using the claimed method. With subclinical mastitis she was 94.1%, sero - 93,3%, catarrhal, there were 92.8%, with purulent-catarrhal - 90,0%, which is higher than when using the prototype method, respectively 6.2%, 10,0%, 178% and 27.5%.

Example 3. The studies were performed on 106 ewes belonging PZ "Shali breakers" Nagai district of the Republic of Dagestan.

Animals of the experimental group (n=55) was injected intramuscularly the drug for the claimed method in a dose of 0.05 ml/kg of animal weight once a day until clinical recovery, control (n=51) - the drug according to the method prototype in accordance with the instruction manual.

Test therapeutic efficacy was conducted on the background of the subcutaneous injection of oxytocin at a dose of 10 IU twice with an interval of 12 h and nademanee novocaine blockade by D. D. Logvinov by a double injection of 0.25% solution of novocaine at a dose of 0.5 ml per 1 kg of body weight at intervals of 48 h. the test Results are presented in table 3.

4,7±0,6
Table 3
The effectiveness of the proposed method for mastitis in lactating sheep in PZ "Shali breakers" Nagai district, Republic of Dagestan
MethodsThe treated goal.Recovery time, daysRecovered
ewes%
Subclinical mastitis
The inventive method172,7±0,21694,1
Method-prototype163,2±0,11487,5
Serous mastitis
The inventive method133,7±0,412the 92.3
Method-prototype143,9±0,51178,5
Catarrhal mastitis
The inventive method143,3±0,31292,8
Method-prototype123,3±0,31083,3
Purulent-catarrhal mastitis
The inventive method1110at 90.9
Method-prototype94,7±0,4666,6

The most high therapeutic efficiency is achieved when using the claimed method. With subclinical mastitis she was 94.1%, sero - 92,3%, catarrhal, there were 92.8%, with purulent-catarrhal - of 90.9%, which is higher than when using the prototype method, respectively, 6.6%, and 13.8%, 9,5% and 24.3%.

Thus, the tests of the claimed method of treatment of mastitis in lactating sheep showed that he has a pronounced therapeutic effect. The method is technically and economically feasible.

A method for the treatment of mastitis in lactating sheep, including intramuscular teleinterviewer of the drug in a dose of 0.05 ml/kg of body weight once a day for 3-4 days in all forms of mastitis on the background of the subcutaneous injection of oxytocin at a dose of 10 IU twice with an interval of 12 hours and nademanee novocaine blockade by Dmitry Loginov by a double injection of 0.25% solution of novocaine at a dose of 0.5 ml per 1 kg of body weight, every 48 hours, characterized in that as teleinterviewer using the drug following composition, wt. %:

Colistin sulfate4,0-6,0
Tylosin base4,0-6,0
The benzyl alcohol4,0
Water for injections15,0
1,2-propylene Glycol100.0%



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention can be used for the local treatment of trophic ulcers, infected and persistent septic wounds, degrees I-II-IIIA burns, traumatic skin injuries, pyoinflammatory skin diseases, bed sores, etc. The invention refers to a preparation, which contains a streptocide powder 1-2.5 g, Ichthyol ointment 7-10 g and castol oil 87.5-92 ml.

EFFECT: reducing the length of treatment up to 14 days with no side effects.

4 ex

FIELD: medicine.

SUBSTANCE: invention refers to a moulded sorbent with the antibacterial properties for treating endometritis, representing nanodispersed mesoporous carbon having a specific adsorption surface of no more than 50 m2/g and a crushing strength of not less than 20 kg/cm2, containing polyvinylpyrrolidone in an amount of not less than 5.0%, characterised by the fact that it is presented in the form of cylinders 2-4mm in diameter, 15-25mm long with one inner circular passage, to a method of treating it, as well as to a method of treating endometritis.

EFFECT: higher clinical effectiveness.

3 cl, 10 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: group of inventions concerns a method for preparing Sostakovsky balsam containing mixing vinyl butyl ether and butyl alcohol, heating a reaction mass while stirring continuously, feeding a catalyst after achieving the required temperature, decontaminating the prepared polymer, pouring out the polymer heated to 50-70°C into a container through a multilayer filter; the above group also concerns the therapeutic agent possessing the wound-healing, bacteriostatic and analgesic properties and prepared by the above method.

EFFECT: higher yield and purity of the produced preparation as compared to the similar methods with preserving the pharmacological properties inherent to the given preparation.

5 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions concerns using live bacteria of nocardioform actinomycetes group for preparing a pharmaceutical composition and a method of using this composition. What is characterised is using nocardioform actinomycetes having an ability to survive in animal's macrophages; the live bacteria are attenuated by inactivating a gene, which codes a protein involved in destructing methylhexahydroindanedione propionate for preparing the pharmaceutical composition. The presented method for animal treatment for the purpose of protection against a disorder caused by infection by the bacterium of the nocardioform actinomycetes group, involves administering the pharmaceutical composition containing an effective amount of these bacteria into the animal.

EFFECT: presented inventions can be used for preventing the infections caused by nocardioform actinomycetes.

12 cl, 4 dwg, 11 tbl

FIELD: medicine.

SUBSTANCE: invention represents an antibacterial pharmaceutical composition containing clotrimazole, propylene glycol, macrogol 400, macrogol 1,500, macrogol 4,000, poloxamer 338, cetostearyl alcohol, macrogol 20 cetostearyl alcohol, disodium edetate, purified water with the ingredients of the compositions taken in certain proportions, g/100 g.

EFFECT: higher antibacterial and antifungal action.

3 cl, 3 dwg, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to organic chemistry, namely to nitroimidazoxazine derivatives of formula , wherein X represents O, OCH2, OCH2CH=CH or OCH2C≡C; Y represents a group of any of formulas IIa-IIc, wherein means an attachment point to X, and Z in formulas

represents CH2, CH=CH, C≡C or a direct bond; the numbers 2, 3 and 4 are positions of a terminal ring having R1 as a substitute; the terminal ring of formula I comprises C, CH or one nitrogen atom in each position, and each of R1 and R2 in formulas I and IIa represents one or two substitutes found in any accessible position of the ring and independently represents H, F, Cl, CF3, OCF2H, OCF3 or combinations thereof. Besides, the invention refers to a pharmaceutical compound based on a compound of formula I, a method of treating a microbial infection, specific compounds.

EFFECT: there are prepared new compound effective in treating the microbial infections, including in treating the diseases caused by Mycobacterium tuberculosis.

8 cl, 28 dwg, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to composition, suppressing quorum sensing. Composition, suppressing quorum sensing in bacteria, contains two dried water or alcohol extracts from oak bark (Quercus cortex), birch bugs (Betulae gemmae), eucalyptus leaves (Eucalyptus folia) with the specified ratio of components.

EFFECT: composition effectively suppresses quorum sensing in bacteria.

3 dwg, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: therapeutic agent contains an alloy of polyethylene oxide of molecular weight 400 and 1500 as a base and comprises a combination of antiseptic, benzalkonium chloride and metronidazole as therapeutic ingredients. The invention provides preparing the therapeutic agent possessing the antimicrobial, sorption and wound-healing action on local pyoinflammatory processes in soft tissues and mucous membranes, used in surgery, dermatology, obstetrics and gynaecology, otorhinolaryngology.

EFFECT: agent possesses the higher efficacy.

2 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to application of 2-R1-4-R2-6-polynitromethyl-1,3,5-triazines of general formula: , where n=0, X=NO2, Cl, Br, R1=R2=OR3, OAr (R3=CH3, C2H5, CH2(CH2)6CH3, CH2CH2Cl, Ar=metha-C6H4CH3), R1=OR3, OAr, R2=N(C2H5)2; n=1, X=Cl, R1=OR3, R2=NH(CH2)2NH2, N(CH2CH2)2NCH3 as compounds, which possess antibacterial activity.

EFFECT: identification of compounds based on 1,3,5-triazine derivatives, which possess high antibacterial activity.

3 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: method of producing a carbon sorbent with antibacterial and antimycotic properties includes impregnating granules of a carbon hemosorbent with 10-50% aqueous solution of glycolic acid for 7-9 hours at room temperature. The ratio of the hemosorbent to the modifier solution of glycolic acid is 1:1. Further, drying is carried out for an hour at 100-110°C. Polycondensation of glycolic acid on the carbon hemosorbent is carried out in two steps: at 185-205°C for 1 hour, at 215-235°C for not less than 5 hours, on a sand bath. The disclosed modified carbon sorbent with antibacterial and antimycotic properties is granules with a round shape, contains not less than 5% polyglycolide, characterised by a specific adsorption surface area of less than 250 m2/g and total pore volume of less than 0.50 cm3/g.

EFFECT: improved properties of the sorbent.

2 cl, 2 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a stable composition of nanostructured Sildenafil inhibiting cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDEV) containing a nanostructured Sildenafil base or its pharmaceutically acceptable salts having an average particle size of less than approximately 500nm, a stabilising agent, wherein the composition is prepared in a microfluidics-based continuous-flow tank reactor, and the composition possesses a semi-amorphous structure. The group of inventions also concerns a method for preparing the composition of nanostructured Sildenafil; using the above composition for preparing the pharmaceutical composition for treating male or female sexual dysfunction and pulmonary arterial hypertension.

EFFECT: group of inventions provides the improved solubility of the composition.

8 cl, 11 ex, 14 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula (I), which can be used for treating diseases mediated by an androgen receptor. In formula (I), R1 means (C2-6)alkyl, (C1-6)alkyloxy, -S(O)m-(C1-6)alkyl, (C1-6)fluoroalkyl, CN or halogen, R2 and R3 are identical or different and mean a hydrogen atom or (C1-9)alkyl, R4, R5, R6, R7 are identical or different and mean a hydrogen or halogen, X means CH or N, Y means either a nitrogen atom, or a carbon atom substituted by (C1-6)alkyl, (C1-6)alkyloxy, (C1-6)fluoroalkyl, a hydrogen atom or halogen; m is equal to 0, 1 or 2.

EFFECT: invention refers to using the compounds for preparing a therapeutic agent for preventing and/or treating hirsutism, androgenetic alopecia, hypertrichosis, atopic dermatitis, disordered sebaceous gland, such as hyperseborrhea, acne, greasy skin or seborrheic dermatitis.

8 cl, 2 tbl, 26 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intravaginal administration of probiotic preparation "Giprolam" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574). "Giprolam" is administered for 5-7 days prior to calving daily at a dose of 100 cm3.

EFFECT: use of the claimed invention promotes to maintain the amount of lactobacilli and bifidobacteria at the physiological level, prevents the colonisation of the genital tract with potentially pathogenic microflora and prevents the occurrence of postpartum infections.

6 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the combined use of the tissue preparation on the 1, 3 and 5 days of treatment, and 15% solution of ASD-2f on tetrahydrovit at a dose of 10 ml intramuscularly on the 2, 4 and 6 days of treatment. The tissue preparation is used as biogenic stimulator aminoseleton which is administered subcutaneously into the upper third of the neck in increasing dose of 40-45-50 ml.

EFFECT: method is highly effective for treatment of subclinical mastitis in lactating cows.

3 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of animals with postpartum endometritis.

4 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the use of chemotherapeutic agents. The chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of endometritis in animals.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and medical equipment, namely to obstetrics and gynaecology, and can be used for the local treatment of inflammatory diseases of the uterine cavity. The method is implemented by inserting a waveguide of a presented device in a protection enclosure into the uterine cavity. A taper base of a narrow portion of the enclosure leans on an external orifice of the cervical uterus to prevent accidental perforation of the uterus. An infusion system regulator is used to set the spray supply of a therapeutic solution into an irrigation canal of the ultrasonic device. Thereafter ultrasonic vibrations are generated, and the uterine cavity is treated with the sounded therapeutic solution. The exposure length is 3-5 minutes at the ultrasonic vibration frequency of 25 kHz, infusion rate approximately 100-150 ml/min. The total infusion volume is not less than 300 ml. The ultrasonic treatment enables providing the continuous outflow of the uterine discharge. The device comprises an US generator, an acoustic assembly, the waveguide with the protection enclosure, the infusion system for the therapeutic solution supply. The acoustic assembly and waveguide comprises the irrigation canal. A working tip of the waveguide represents a short cylinder having a diameter greater than the rest portion. The irrigation canal of the waveguide has a diameter of 2 mm. The protection metal thin-wall enclosure has a crimped distal end and drain holes and represents two cylindrical elements of various diameters connected by a taper junction with milled grooves arranged so that to enable the fluid access to the working tip cylinder, the length of which makes no more than 3 mm.

EFFECT: inventions provide the effective cleansing of the uterine cavity from infected and necrotised tissues with improved comfort and safety of the procedure with using no endoscopic equipment, cervical dilation manipulations and uterine pre-probing.

2 cl, 3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, particularly to an agent for treating and preventing endometritis in animals. The substance of the invention consists as follows. Novocaine 0.5 g is dissolved in distilled water 1 l, and the following preparations are dissolved in a solution of Novocaine 250 mg: powdered metronidazole 4.0 g is dissolved in Novocaine 250 ml; powdered ciprofloxacin 2.0 g is dissolved in Novocaine 250 ml; powdered Doxycycline 1.0 g is dissolved in Novocaine 250 ml; powdered tavegil 2.5 g is dissolved in Novocaine 250 ml; all the ingredients are combined to prepare the agent in an amount of 1 litre for treating and preventing endometritis in animals.

EFFECT: invention provides the pronounced anti-inflammatory and antimicrobial effect of a broad spectrum of action combined with reducing the body response to histamine, relieving smooth muscle spasm and reducing capillary penetration.

5 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.

EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.

4 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating and managing the pregnant women suffering drug-induced hepatitis. Establishing a diagnosis of drug-induced hepatitis requires oral administration of the herbal hepatoprotectors Carsil, or Hepabene, or the vitamin-free essential phospholipids Eslidin per os or Essentiale forte N intravenously, per os in standard doses with a cessation of any other drug-induced therapy, in the 1st trimester of pregnancy in case of observing a symptom-free increase of transaminase activity within 3 normal values and no counter-indications. In the 2nd trimester, a serum transaminase level up to 5 normal values requires prescribing ademetionine 400 mg intravenously N 7-10, then per os 1,600 mg/day. The therapeutic course makes 1 month. Ademetionine 800 mg intravenously N 10 + ursodeoxycholic acid 12 mg/kg/day are prescribed if observing the daily serum transaminase level of 5 to 10 normal values. Prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 12 mg/kg/day + prednisolone 90 mg/day is used for the daily serum transaminase level of more than 10 normal values. In the 3rd trimester, the daily serum transaminase level of below 5 normal values requires administering ademetionine 800 mg/day intravenously N10 + ursodeoxycholic acid 13 mg/kg/day. The transaminase level of 5 to 10 normal values requires prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 13 mg/kg/day + prednisolone 90 mg/day intravenously. A progressive increase of the daily transaminase level of above 10 normal values with underlying therapy with ademetionine 800 mg/day intravenously, ursodeoxycholic acid 13 mg/kg/day, prednisolone 120 mg/day intravenously with 3 days expected, a decrease of the daily transaminase level or a stabilization thereof are accompanied by continuing the therapy with the progression follow-up, including hepatic cytolysis values - an increase of the hepatic cytolysis values; an increase thereof is accompanied by prescribing the adequate therapy. The postpartum therapy is continued completely until liver function tests are normalised.

EFFECT: method enables preventing the pregnancy complications ensured by the timely diagnosis of drug-induced hepatitis in the pregnant women, the adequate drug-induced therapy differentiated by gestational age and a degree of manifestation of hepatic cytolysis and aiming at reducing a hepatic pathological process.

6 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

Up!